149 related articles for article (PubMed ID: 28202518)
1. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.
Sundaram KM; Zhang Y; Mitra AK; Kouadio JK; Gwin K; Kossiakoff AA; Roman BB; Lengyel E; Piccirilli JA
Cancer Res; 2017 Apr; 77(7):1684-1696. PubMed ID: 28202518
[TBL] [Abstract][Full Text] [Related]
2. A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.
Hoogstins CE; Tummers QR; Gaarenstroom KN; de Kroon CD; Trimbos JB; Bosse T; Smit VT; Vuyk J; van de Velde CJ; Cohen AF; Low PS; Burggraaf J; Vahrmeijer AL
Clin Cancer Res; 2016 Jun; 22(12):2929-38. PubMed ID: 27306792
[TBL] [Abstract][Full Text] [Related]
3. MRI for discriminating metastatic ovarian tumors from primary epithelial ovarian cancers.
Xu Y; Yang J; Zhang Z; Zhang G
J Ovarian Res; 2015 Aug; 8():61. PubMed ID: 26310488
[TBL] [Abstract][Full Text] [Related]
4. Diffusion kurtosis imaging for differentiating borderline from malignant epithelial ovarian tumors: A correlation with Ki-67 expression.
Li HM; Zhao SH; Qiang JW; Zhang GF; Feng F; Ma FH; Li YA; Gu WY
J Magn Reson Imaging; 2017 Nov; 46(5):1499-1506. PubMed ID: 28295854
[TBL] [Abstract][Full Text] [Related]
5. CT and MRI findings of type I and type II epithelial ovarian cancer.
Liu D; Zhang L; Indima N; Peng K; Li Q; Hua T; Tang G
Eur J Radiol; 2017 May; 90():225-233. PubMed ID: 28583639
[TBL] [Abstract][Full Text] [Related]
6. The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas.
Yuan SJ; Qiao TK; Qiang JW; Cai SQ; Li RK
J Ovarian Res; 2017 Sep; 10(1):65. PubMed ID: 28950890
[TBL] [Abstract][Full Text] [Related]
7. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
[TBL] [Abstract][Full Text] [Related]
8. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.
Oren R; Addadi Y; Narunsky Haziza L; Dafni H; Rotkopf R; Meir G; Fishman A; Neeman M
Int J Cancer; 2016 Oct; 139(8):1788-98. PubMed ID: 27242346
[TBL] [Abstract][Full Text] [Related]
10. MRI features and score for differentiating borderline from malignant epithelial ovarian tumors.
Li YA; Qiang JW; Ma FH; Li HM; Zhao SH
Eur J Radiol; 2018 Jan; 98():136-142. PubMed ID: 29279152
[TBL] [Abstract][Full Text] [Related]
11. Application of apparent diffusion coefficient and exponent apparent diffusion coefficient values in magnetic resonance imaging diffusion-weighted imaging to differentiate benign and malignant ovarian epithelial tumors.
Wang YX; Yuan MZ; Wen ZX
J Cancer Res Ther; 2016; 12(1):401-5. PubMed ID: 27072270
[TBL] [Abstract][Full Text] [Related]
12. Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer.
Liao S; Lan X; Cao G; Yuan H; Zhang Y
Clin Nucl Med; 2013 Sep; 38(9):715-20. PubMed ID: 23856825
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol inhibits ovarian tumor growth in an in vivo mouse model.
Tan L; Wang W; He G; Kuick RD; Gossner G; Kueck AS; Wahl H; Opipari AW; Liu JR
Cancer; 2016 Mar; 122(5):722-9. PubMed ID: 26619367
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer.
Meng W; Ying W; Qichao Z; Ping L; Jie T
Saudi Med J; 2017 Jun; 38(6):592-597. PubMed ID: 28578437
[TBL] [Abstract][Full Text] [Related]
16. Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings.
Katabathina VS; Amanullah FS; Menias CO; Chen MM; Valente PT; Chintapalli KN; Prasad SR
Radiographics; 2016; 36(3):918-32. PubMed ID: 27163599
[TBL] [Abstract][Full Text] [Related]
17. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
18. Relative localization of the prolactin receptor binding sites for lactogenic hormones.
Longhi SA; Blank VC; Roguin LP; Cristodero M; Retegui LA
Growth Horm IGF Res; 2001 Oct; 11(5):324-8. PubMed ID: 11735251
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer.
Yang W; Cho H; Shin HY; Chung JY; Kang ES; Lee EJ; Kim JH
Oncotarget; 2016 Aug; 7(31):49481-49497. PubMed ID: 27385216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
